SCHEMBL2391830

SCHEMBL2391830

NC(=O)C(F)c1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 2/20 0.45
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
MAOB P27338 1/20 0.43
SLC9A1 P19634 3/20 0.41
IKBKB O14920 2/20 0.41
TDO2 P48775 1/20 0.40
PARP1 P09874 1/20 0.40
IDO1 P14902 1/20 0.40
NUDT1 P36639 1/20 0.40
RORB Q92753 1/20 0.39
CNR2 P34972 1/20 0.39
NAT1 P18440 1/20 0.39
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2389641 0.87 HSP90AA1 (0.47) HSP90AA1HSP90AB1CHRM1CHRM3MAOB
SCHEMBL9890803 0.84 CHRM1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3MAOB
SCHEMBL2393361 0.84 MAOB (0.43) MAOBSLC9A1PARP1FGFR1FGFR3
SCHEMBL2393686 0.82 BCAT2 (0.48) HSP90AA1HSP90AB1FGFR1SRCFGFR2
SCHEMBL9890801 0.82 CXCL8 (0.48) HSP90AA1HSP90AB1CHRM1CHRM3MAOB
SCHEMBL2393363 0.79 RORC (0.43) HSP90AA1HSP90AB1CHRM1CHRM3SLC9A1
SCHEMBL9890685 0.75 PTGS2 (0.53) HSP90AA1HSP90AB1CHRM1CHRM3MAOB
SCHEMBL3632126 0.73 BCAT2 (0.65) CHRM1CHRM3SLC9A1IKBKBPARP1
SCHEMBL9890709 0.71 HSP90AA1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3RORB
SCHEMBL9890688 0.71 HSP90AA1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3RORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSP90AA1 1699/4885HSP90AB1 2118/4885CHRM1 340/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSP90AA1 1699/4885HSP90AB1 2118/4885CHRM1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.